Wells Fargo analyst Mohit Bansal raised the firm’s price target on Eli Lilly to $1,000 from $875 and keeps an Overweight rating on the shares. The global appetite for Mounjaro and Zepbound could drive a $100B opportunity, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- LLY Earnings: Eli Lilly Reports Impressive Q2 Results; Huge Revenue Increase
- Options Volatility and Implied Earnings Moves Today, August 08, 2024
- Eli Lilly raises FY24 EPS view to $16.10-$16.60 from $13.50-$14.00
- Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion
- Eli Lilly reports Q2 EPS $3.92, consensus $2.60
Questions or Comments about the article? Write to editor@tipranks.com